RYAM Filed Its Sale Plans. It Didnt Say What Was Actually for Sale.
RYAM confirmed on May 5 what it announced on April 20. The sale process is real. The scope is not.
The SEC 8-K filing dated May 5 confirms a formal strategic review is underway, with Morgan Stanley and Wachtell, Lipton, Rosen & Katz advising. It does not specify which assets or product lines are in play. The high-purity cellulose segment, the paperboard and high-yield pulp businesses, the idled Temiscaming plant — the filing is silent on all of it. Nobody outside the boardroom knows what is actually for sale. That silence is the story.
The quarterly numbers underneath explain why the board moved. RYAM reported a net loss of $81 million in Q1 2026 — 2.5 times the $32 million loss a year earlier — on revenue of $319 million, down 10.4% from the year-ago quarter, per the SEC filing. Operating earnings adjusted to exclude one-time charges — what the company calls Adjusted EBITDA, a non-GAAP figure that adds back idling costs and similar items to show underlying cash generation — fell to $8 million from $17 million in Q1 2025, the Benzinga earnings call transcript from May 6 shows. Those are not rounding errors.
CEO Scott Sutton resigned on April 20, having joined in January — a tenure of roughly three months, per the Jax Daily Record. The stock fell 19% on the announcement before recovering to an 88% quarterly gain — the best performance of any Jacksonville-based company in the period, the Jax Daily Record reported. That rally prices in a sale process, not a turnaround. RYAM declined to name potential buyers or specify a timeline.
American Industrial Partners made an unsolicited offer in November 2025 that RYAM's board rejected in December, the Jax Daily Record reported. AIP did not disclose the offer publicly until February. What changed between December's rejection and April's announcement is not explained in any filing, raising the possibility that the strategic review is managing a major shareholder rather than running a genuine auction.
RYAM reported a net loss of $420 million in 2025, its seventh consecutive year of losses from continuing operations, per the Jax Daily Record. Total debt stands at $763 million, with a covenant net secured leverage ratio of 4.3x, the SEC filing shows.
The high-purity cellulose segment contributed $24 million in Q1 adjusted EBITDA, per the Benzinga transcript, which annualizes to roughly $96 million. At a specialty chemicals M&A multiple of 6 to 8 times EBITDA, that segment alone might be worth $575 million to $770 million on a standalone basis. The problem is the debt stack. Total debt of $763 million sits above equity at any realistic valuation of the operating business, which means any buyer is acquiring equity against a $763 million liability rather than free of it. The net secured leverage ratio of 4.3x further restricts how much additional borrowing a new owner can layer on top, capping the equity value effectively at zero for a buyer who cannot extract operational improvements. Whether a strategic buyer pays a premium for the HPC product lines and customer relationships is the unresolved question the process is designed to answer.
The permanently idled Temiscaming plant carries a $41 million non-cash charge and no near-term revenue offset, which works against a whole-company premium. What a buyer acquires in practice is a high-purity cellulose business used in specialty filtration, food packaging, and defense-adjacent applications — a consolidating supply chain where capacity has value and a strategic buyer might pay more than the operating floor warrants. New products planned for H2 2026 include materials for freezer board and odor control applications, per the Benzinga transcript. Management's full-year guidance calls for EBITDA above 2025 levels and positive free cash flow, per the SEC filing. At an $8 million Q1 adjusted EBITDA run rate, meeting that target requires roughly tripling the quarterly run rate over the remaining three quarters, which the company's financial profile does not obviously support absent a step change in operating conditions.
The strategic review is the board's answer to a problem it has not solved in seven years of losses. Whether anyone shows up with a check large enough to matter against $763 million in debt and a 4.3x leverage ratio is an open question. RYAM declined to comment on specific bidders or timeline.